Physician profile
Stephen Dickson
NPI 1023422474
$97,810.02
in general payments reported to CMS, 2019-2025
39 companies · $19K in 2025
The $19K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $369 · 2021: $1,249 · 2022: $22K · 2023: $28K · 2024: $27K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Food and Beverage: $5,168 · Consulting Fee: $4,650 · Travel and Lodging: $2,450 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,920.00 |
| Food and Beverage | $5,167.66 |
| Consulting Fee | $4,650.00 |
| Travel and Lodging | $2,450.30 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $74,118.25 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $12,128.76 | 2022-2025 | Jardiance, Mounjaro |
| Novo Nordisk INC | $5,042.45 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Boston Scientific Corporation | $1,255.47 | 2020-2025 | Watchman Flx, Watchman Access System, Farapulse |
| Novartis Pharmaceuticals Corporation | $977.11 | 2021-2025 | |
| Amgen INC. | $815.20 | 2020-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $549.02 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $359.73 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $354.84 | 2020-2024 | Xarelto |
| Pfizer INC. | $322.61 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $214.26 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals Lp | $183.78 | 2021-2025 | Wainua, Lokelma |
| Abiomed | $144.42 | 2019 | |
| Sanofi-Aventis U.S. LLC | $113.78 | 2021-2023 | |
| Vital Connect, INC | $99.59 | 2024-2025 | Vitalpatch Rtm |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.